I'm staying until the SNT 6302 results are out in December at...

  1. 13,489 Posts.
    lightbulb Created with Sketch. 7298
    I'm staying until the SNT 6302 results are out in December at the very least .
    Highly Visual and easily understood by the market , Fiona Wood "Scar Reduction ... That is Unprecedented with SNT 6302."
    This from the Investor of Spray on Skin and who consults on Scar Reduction Worldwide....

    Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars

    Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars

    Beyond the searing pain of burns, permanent scarring of the skin has a devastating lifelong impact on quality of life. Imagine reaching up for the top shelf and having a sharp pain surge down your arm and back. Unfortunately this is the reality for millions of burn victims where skin does not heal with the same elasticity as it’s natural form, instead tightened to the point where stretching can cause intense pain.

    Having benefited the lives of countless patients as the pioneer of spray-on-skin and a world-leading esteemed expert in burns, Professor Fiona Wood has been alongside many victims through their recovery journeys. Seeing this tightening of the healed skin and its ongoing mental impact on patients, she has made it her mission to reverse the impacts of burns, essentially to ‘un-scar the scar’.

    Her tireless dedication to advancing burn care earned her international acclaim and recognition.

    In 2023, Professor Wood led clinical trials conducted at the University of Western Australia, identifying a drug developed by biotech company Syntara (ASX: SNT) as one that could reinvigorate elasticity of the skin in scar tissue.

    Syntara’s pan LOX (lysyl oxidase) inhibitors caught her attention, with potential to inhibit the enzymes that create scar tissue. Research was put into clinical trials in 2023 with 42 patients volunteering to apply the topical cream to their scars in a 3-month study.

    The results were highly encouraging, showing 66% reduction in LOX enzyme activity which is responsible for the cross linking of collagen fibres implicated in adverse scarring. Collagen was reduced by 30%, a result Professor Wood described as “an unprecedented change to the scar composition that we have not seen with any other form of treatment.”


    Fully Funded ,, I Believe 80% recruitment is Completed , Trial Results to be presented in the United States in December....NZT $$$

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
5.1¢
Change
0.004(8.51%)
Mkt cap ! $82.87M
Open High Low Value Volume
4.8¢ 5.4¢ 4.7¢ $857.5K 17.69M

Buyers (Bids)

No. Vol. Price($)
2 69701 5.0¢
 

Sellers (Offers)

Price($) Vol. No.
5.2¢ 70931 3
View Market Depth
Last trade - 16.10pm 24/06/2025 (20 minute delay) ?
SNT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.